Not Yet Recruiting Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study NCT06785584 Conditions ALK-positive Advanced NSCLC, ALK-positive Non-small Cell Lung Cancer (NSCLC), MPR, +1 more Locations Fujian Medical University Union Hospital — Fuzhou, Fujian, China View Trial Details
Completed A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib NCT03535740 Conditions ALK-positive Advanced NSCLC Locations University of California Irvine Health Chao Family Comprehensive Cancer Center — Orange, California, United States The Oncology Institute of Hope and Innovation — Whittier, California, United States USOR - Rocky Mountain Cancer Centers - Pueblo — Pueblo, Colorado, United States Florida Hospital Medical Group — Orlando, Florida, United States View all 80 locations View more locations Show fewer locations Loading locations... View Trial Details
Completed Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) NCT03410108 Conditions ALK-positive Advanced NSCLC Locations Aichi Cancer Center Hospital — Nagoya, Aichi-ken, Japan Nagoya University Hospital — Nagoya, Aichi-ken, Japan Fujita Health University Hospital — Toyoake, Aichi-ken, Japan National Cancer Center Hospital East — Kashiwa, Chiba, Japan View all 33 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment NCT07567352 Conditions ALK-positive Advanced NSCLC, ALK-positive NSCLC, ALK-positive Non-small-cell Lung Cancer, +11 more Locations Pfizer — New York, United States View Trial Details
